The efficacy of CB-103, a first-in-class transcriptional Notch inhibitor, in preclinical models of breast cancer
M. Vigolo, C. Urech, S. Lamy, G. Monticone, J. Zabaleta, F. Hossain, D. Wyczechowska, L. Del Valle, R. O'Regan, L. Miele, R. Lehal, S. Majumder
This paper evaluates the efficacy and safety of CB-103, a Notch inhibitor, in preclinical breast cancer models, showing synergistic effects with existing therapies.
bioRxiv · Jul 6, 2023Cancer Biology